1 / 63

Clinical Enzymology

Clinical Enzymology. FE A. BARTOLOME, MD, DPASMAP Dept. of Pathology & Laboratory Diagnosis Our Lady of Fatima University. ENZYMES. protein molecules catalyze chemical reactions without themselves being altered chemically contained primarily within cells

issac
Download Presentation

Clinical Enzymology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Enzymology FE A. BARTOLOME, MD, DPASMAP Dept. of Pathology & Laboratory Diagnosis Our Lady of Fatima University

  2. ENZYMES • protein molecules • catalyze chemical reactions without themselves being altered chemically • contained primarily within cells • essential enzymes present in virtually all organs but with slightly different forms in different locations  isoenzymes • classified according to biochemical functions • unit of enzyme activity: • 1 IU = transform 1 mol of substrate/minute • 1 SI (katal) = transform 1 mol substrate/second

  3. Indicators of Cardiac Injury Creatine kinase (CK) • creatine phosphokinase (CPK) • catalyze transfer of a PO4 group between creatine PO4 & ADP to form creatine + ATP • requires magnesium as cofactor • dimeric with pair of two different monomers  M & B • 3 isozymes: CK1 (BB), CK2 (MB), CK3 (MM) • M and B subunits antigenically distinct proteins encoded by different genes

  4. Creatine kinase (CK) • primary tissue sources: • Brain, smooth muscle, prostate, thyroid, gut, lung  CK-BB • Cardiac muscle – MB (20-30%) & MM (70-80%) • Skeletal muscle – MB (1-2%) & MM (98-99%) • Plasma – predom. MM with < 6% MB • relatively small molecular size  allows leakage out of ischemic muscle or brain cells

  5. Creatine kinase (CK) • reference ranges in serum affected by: • Amount of lean muscle mass • Thin, sedentary = 30 – 50 U/L • Muscular, exercising regularly = 500 – 1000 U/L • Age – in neonates, CK-MB 5-10% of total CK • Gender • Race – Africans 30% higher than Europeans • Muscle activity – direct relationship between intensity of exercise and CK level

  6. Creatine kinase (CK) • persons exercising periodically & at usual intensity levels with lower CK than those who do not exercise at all • decrease with severe inactivity • short-term strenuous exercise  10-100 fold increase • marathon runners  up to 2000 U/L as resting value

  7. Diagnostic Applications CM-MM • released from damaged muscles: CK, AST, LD, myoglobin • Myoglobin >> CK >> AST and LD • released during ischemia, injury or inflammation • also increased in: • Chronic myopathies • Chronic renal failure • Acute respiratory exertion – respiratory muscles with more CK than other muscles

  8. Diagnostic Applications CK-BB • Brain trauma or brain surgery • Injury to smooth muscles (e.g. intestinal ischemia) • Patients with malignancies, esp. prostate cancer, small cell lung CA, intestinal malignancies  synthesize B subunit • Transient increase after cardiac arrest  reflect cerebral ischemia

  9. Diagnostic Applications CK-MB • primary clinical use: detection of acute MI • Following MI: • Total CK – 98% sensitive but 68-85% specific; peak value 18-30 hrs; duration 2-5 days; level 5-10x normal • CK-MB – rise proportional to extent of infarction; appears in serum within 6 hrs after AMI; peak value 12-24 hrs; duration 1.5-3 days  persistence indicates extension or infarction or re-infarction

  10. Diagnostic Applications Total Serum CK • Normal: 24 – 170 U/L (women) 24 – 195 U/L (men) • Marked elevation (> 5x normal) • After trauma from electrocution, crush injury, convulsion, tetany, surgical incision or IM injection • Athletic individuals – inc. muscle mass & inc. release during strenuous activity • Muscular dystrophies • Chronic inflammation of muscle (dermatomyositis or polymyositis)

  11. Diagnostic Applications Total Serum CK • Mild or moderate elevation (2 – 4x normal) • Hyper- or hypothermia • Hypothyroidism • After normal vaginal delivery – BB isoenzyme from myometrial contractions • Reye’s syndrome

  12. Atypical Isoenzymes • Forms that migrate electrophoretically in positions different from standard ones • Adenylate kinase • Catalyze formation of ATP & AMP from ADP • Released from erythrocytes • Macro CK type 1 – complex of CK (BB) with antibody (IgG)  mistaken for CK-MB; no known clinical significance • Macro CK type 2 – oligomeric variant of CK; mitochondrial • If (+) in serum – poor prognostic sign • (+) in patients with malignancies & moribund patients

  13. Lactate dehydrogenase (LD) • Zinc-containing; part of glycolytic pathway • Catalyze conversion of lactate to pyruvate using NAD+ as cofactor • CH3 CH3 • HCOH + NAD+ C = O + NADH + H+ • COOH COOH • Tissue source: present virtually in all tissues  cytoplasm of all cells and tissues in the body • Tetramers with 4 subunits of 2 possible forms: H (heart) and M (muscle)

  14. Lactate dehydrogenase (LD) • Five isoenzymes: • LD1 & LD2 – high in heart muscle, erythrocytes, kidney • LD4 & LD5 – high in skeletal muscle & in liver • Normal pattern in serum: • LD2 > LD1 > LD3 > LD4 > LD5 • Highest in newborns and infants; values do not change with age in adults • No gender difference

  15. DIAGNOSTIC APPLICATIONS: • Total LD activity: increase in any disease state where there is cell damage or destruction  non-specific  correlate with AST, ALT and CK • Markedly inc. LD with normal or minimally inc. AST, ALT & CK  damage to biochemically simple cells (e.g. rbc, wbc), kidney, lung, LN or tumors • Inc. LD & CK; inc. AST > ALT  cardiac or skeletal muscle injury • AST & ALT inc. > LD  transiently in liver disease (toxic or ischemic liver injury)

  16. Myocardial damage – • Myocardium normally with LD1 > LD2  similar to rbc • Acute myocardial infarction: • Inversion or flipped LD1/LD2 ratio to a value > 1.0 in serum  stay flipped for several days • Levels inc. after 12-24 hrs, peak (2-10x normal) at 48-72 hrs, return to normal after 8-10 days • used to confirm diagnosis of MI when CK isoenzyme analysis equivocal or after total CK & CK-MB release has returned to normal

  17. Other Applications • Total LD used to estimate tumor mass including metastases • LD1 or LD2 inc. in germ cell tumors (seminoma & dysgerminoma) – serve as tumor marker • Flip LD1/LD2 ratio: • Extreme exercise • Acute myocardial infarction • Hemolytic anemia • Megaloblastic anemia • Renal cortical disease (renal infarct, renal cell CA)

  18. Other Applications • Inc. LD2, 3 and 4 – malignancy & large tumor burden • Inc. LD3 & 4, dec. LD1 & 2 – WBC tumors (leukemia, lymphoma, MM), pulmonary disease • Inc. LD4 & 5 – skeletal muscle injury, ischemic or toxic hepatic injury • Isomorphic pattern – inc. total LD, normal isoenzymes with “tombstone” pattern (relative amounts of isoenzymes the same)  diffuse tissue damage accompanied by shock or hypoxemia

  19. Myoglobin • Small; functions in storage and transfer of O2 from Hgb in the circulation to intracellular respiratory enzymes of contractile cells • With greater affinity for oxygen than Hgb • Only one molecular form • One of the first to diffuse out of ischemic muscle cells, even before CK • Cleared from circulation by kidneys • Measurement in serum with high sensitivity for muscle injury, including acute MI  measure by immunoassay

  20. Myoglobin • In normal individuals, • Levels related to muscle mass and activity • Males > females • Africans > Europeans • Increase with increasing age due to decreasing GFR

  21. Troponins • Bind tropomyosin and govern excitation-contraction coupling • Three subunits • Troponin C (TnC) – calcium-binding subunit • Troponin I (TnI) – bind to actin  inhibitory • Troponin T (TnT) – bind to tropomyosin • TnI and TnT with unique forms expressed in myocardial cells but not in other muscle types  presence of cTnI or cTnT in serum highly specific for myocardial injury

  22. Troponins • cTnT • 84% sensitivity for MI 8 hrs after onset of symptoms • 81% specificity for MI; 22% specificity for unstable angina • cTnI • 90% sensitivity for MI 8 hrs after onset of symptoms • 95% specificity for MI; 36% specificity for unstable angina

  23. Troponins • Cardiac troponins released in two phases: • Initial damage (acute MI) – leave myocardial cells  enter circulation the same time that CK-MB does  peak at 4-8 hrs • Sustained release from intracellular contractile apparatus – occurs up to days after acute event • First appear in circulation ff. myocardial injury slightly later than when myoglobin enters the blood  rises after 3-6 hrs  peaks at ~ 20 hrs

  24. Troponins • General advantages: • cTnT and cTnI are released only following cardiac damage. • Unlike CK & CK-MB, cTnT and cTnI are present , and remain elevated, for a long time  cTnI detectable up to 5 days & cTnT for 7-10 days following MI • cTnT and cTnI are very sensitive.

  25. Troponins • General disadvantages: • Elevation can occur as a result of causes other than MI  myocarditis, severe cardiac failure, cardiac trauma, pulmonary embolus with cardiac damage • Failure to show a rise in cTnT or cTnI does not exclude the diagnosis of ischemic heart disease. • Both may be elevated in patients with chronic renal failure with sustained levels of elevation.

  26. Troponins • Measured in serum by immunoassay • Ideal time to check is between 6 and 9 hours from onset of symptoms • If onset of symptoms indistinct – take sample on admission, 6 – 9 hrs after and at 12 – 24 hrs after admission

  27. Other enzymes useful in clinical diagnosis Acid phosphatase (ACP) • Optimal activity: pH 5.0 • Tissue source: • Common to many tissues, esp. prostate • Small amounts in rbc, platelets (during clot formation), liver and spleen • Human milk and seminal fluid (very concentrated)

  28. Acid phosphatase (ACP) • Prostatic ACP distinguished from others using thymolphthalein monophosphate highly specific for prostatic ACP • Major applications: • Evaluation of prostatic CA (metastatic & local growth) • Not elevated in CA confined within prostate, BPH, prostatitis or ischemia of prostate • Medicolegal evaluation of rape – vagina with little or no ACP • Measured by radioimmunoassay  acidify serum with citric acid to stabilize ACP activity

  29. Alkaline phosphatase (ALP) • Widely distributed along surface membranes of metabolically active cells • Encoded for by four different genes expressed in: • Placenta • Intestines • Germ cell and lung • Tissues including bone, liver, kidney & granulocyte • Very high activity in bone, liver, intestine, kidney, wbc and placenta

  30. Alkaline phosphatase (ALP) • Methods for distinguishing ALP isoenzymes: • Heat fractionation – easiest & most common; heat serum sample at 56oC x 15 min. then compare with unheated sample • Bone ALP extremely labile  retain 10-20% of original activity • Liver & placental ALP heat stable  liver ALP 30-50% retained, placental ALP with all retained • Chemical inhibition • Urea – block placental ALP • Phenylalanine – block liver & bone ALP • Electrophoresis - definitive

  31. DIAGNOSTIC APPLICATIONS Liver ALP • Derived from epithelial cells of biliary tract  excreted by bile into intestine • Used for establishing diagnosis in jaundice • Pronounced increase (> 5x) • Intra- or extrahepatic bile duct obstruction • Biliary cirrhosis • Moderate increase (3-5x normal) : granulomatous or infiltrative liver disease • Slight increase (up to 3x normal) : viral hepatitis, cirrhosis

  32. Bone ALP • Elevation part of osteoblastic growth • Pronounced increase: • Paget’s disease • Osteogenic sarcoma • Hyperparathyroidism • Moderate increase: metastatic tumors in bone; metastatic bone disease (rickets, osteomalacia) • Slight increase: healing fractures; normal growth patterns in children

  33. Placental ALP • With oncofetal form  turned on and expressed by tumor cells in adults  called Regan isoenzyme • Slight increase in pregnancy • Intestinal ALP • Inc. in inflammatory bowel disease (ulcerative colitis & regional enteritis) • Secreted into the circulation after a meal in persons with blood type “O” and “B”  inc. total ALP in non-fasting specimens

  34. Renal ALP • Normally excreted into urine from renal tubular cells • Granulocyte ALP • Used as marker of granulocyte maturity in leukocytosis • Lymphocytes infected with HIV  release specific ALP fraction (band-10)  surrogate marker for HIV infection in children

  35. Aldolase • Glycolytic enzyme  split fructose-1,6-diphosphate into two triose phosphate molecules in glucose metabolism • Distributed in all tissues • Elevated in serum following: • Skeletal muscle disease or injury – reflect severity of dermatomyositis • Metastatic CA to liver 5. Hemolytic anemia • Granulocytic leukemia 6. Tissue infarction • Megaloblastic anemia

  36. Aminotransferase (Transaminase) • Catalyze reversible transfer of an amino group between an amino acid and an alpha-keto acid • R R’ R R’ • HCNH2 + C = O C = O + HCNH2 • COOH COOH COOH COOH • Requires pyridoxal phosphate (vitamin B6) as cofactor

  37. Alanine aminotransferase (ALT) • “glutamate-pyruvate transaminase” (GPT) • Rich amounts in hepatocytes  with high specificity for liver damage • Moderate amount: kidney, heart, skeletal muscle • Small amount: pancreas, spleen, lung, red blood cells

  38. Diagnostic Applications • Inc. AST & ALT – excellent indicators of liver damage • ALT increased in serum ff. acute MI 6 hrs after onset, peaks at 24-48 hrs, returns to normal in 3-4 days • AST inc. in conditions that can be confused with acute MI or that may complicate or co-exist with acute MI: • Shock or circulatory collapse from any cause • Acute pancreatitis • Cardiac arrhythmias or ischemic insult that do not progress to infarction

  39. Gamma glutamyltransferase (GGT) • “gamma glutamyltranspeptidase • Catalyze transfer of glutamyl groups between peptides or amino acids through linkage at a -COOH group  important in transfer or movement of amino acids across membranes • Large amounts in: • Pancreas and renal tubular epithelium • Hepatobiliary cells

  40. Diagnostic Applications • increased activity: • In urine – renal tubular damage • Hepatocellular & hepatobiliary diseases  correlates better with obstruction & cholestasis than with pure hepatocellular damage  “obstructive” enzyme

  41. Diagnostic Applications • GGT & alcohol • Alcohol induces microsomal activity  inc. GGT synthesis  indicator of alcohol use • GGT levels return to normal after 3-6 wks of abstention from alcohol  test for compliance in alcohol-reduction programs

  42. Diagnostic Applications • GGT & drugs • Barbiturates, phenytoin & other drugs (acetaminophen) inc. microsomal activity of GGT • Potentially useful in drug treatment protocols

  43. Amylase (Diastase) • digestive enzyme • Acts extracellularly to cleave starch into smaller groups & finally to monosaccharides • Major sources: salivary glands • exocrine pancreas

  44. Pancreatic amylase • secretion stimulated by pancreozymin (cholecystokinin) • enter duodenum at ampulla of Vater via sphincter of Oddi • Low levels found in: • Fallopian tubes 3. Small intestine • Adipose tissue 4. Skeletal muscle • readily cleared in urine

  45. DIAGNOSTIC APPLICATIONS • Acute Pancreatitis • Levels rise within 6-24 hours remain high for a few days  return to normal in 2-7 days • Serum amylase normal but with suspicion of pancreatitis  measure 24-hour urine amylase or serum lipase

  46. DIAGNOSTIC APPLICATIONS • Morphine administration • Constrict pancreatic duct sphincter  dec. intestinal excretion & inc. absorption in the circulation • Renal failure • Failure to clear normally released amylase from the circulation  no diagnostic significance

  47. DIAGNOSTIC APPLICATIONS • Malabsorption & liver disease • (+) circulating complexes of amylase with a high MW compound such as Ig’s  macroamylasemia  prevent renal clearance • no diagnostic significance

  48. DIAGNOSTIC APPLICATIONS • Tumors • serous ovarian tumors • epithelium similar to FT  produce cyst fluid with amylase  appear in serum & urine • Lung CA • ectopic production of amylase

  49. Conditions Affecting Serum Amylase

More Related